| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $232.7M | +33.9% |
| SG&A Expense | $43.3M | +25.9% |
| Operating Income | -$275.9M | -32.6% |
| Net Income | -$255.9M | -33.0% |
| EPS (Basic) | -$1.94 | +19.8% |
| EPS (Diluted) | -$1.94 | +19.8% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $98.2M | +84.4% |
| Current Assets | $296.5M | +9.5% |
| Total Assets | $327.9M | +4.6% |
| Current Liabilities | $55.7M | +46.0% |
| Total Liabilities | $71.6M | +28.7% |
| Stockholders' Equity | $256.3M | -0.6% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$207.8M | -35.3% |
| Capital Expenditures | $573K | -79.5% |
| Investing Cash Flow | $38.3M | +139.1% |
| Financing Cash Flow | $214.5M | +31.1% |
| Free Cash Flow | -$208.4M | -33.2% |